Genetic testing plays a vital role in diagnosing and treating hematologic malignancies. It enables precise disease classification, prognostic stratification, and personalized treatment planning, guiding targeted therapies and minimizing adverse reactions. By detecting gene mutations and monitoring minimal residual disease (MRD), it helps assess relapse risks and improve patient outcomes.

MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.

Clinical evaluations are systematically carried out centered on five core laboratory divisions (naming varies across hospitals): Cell Morphology Laboratory, Pathological Diagnosis Laboratory, Flow Cytometry Laboratory, Cytogenetics Laboratory, and Molecular Diagnosis Laboratory. Corresponding tests include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, karyotype analysis, FISH, gene testing, etc.

Director Pang Wenjuan gave an example that in her recent consultation with an expatriate couple, in addition to explaining in detail the differences between Chinese and foreign IVF protocols, the hospital's Overseas Medical Department can also assist in providing fertility demand consulting and psychological assessment for fertility preservation (there are also overseas patients coming to China for treatment, such as a recent patient from Bangladesh who requested IVF at Jiahu

Ruijin Hospital Proton Center: Advanced Lung Cancer Treatment for Elderly & Complex Patients. See how 70-year-old Mr. Xu, with multiple health issues, achieved significant tumor shrinkage via precise proton therapy—a "guided missile" approach that spares healthy tissue. We specialize in turning high-risk cases into hopeful recoveries. #ProtonTherapy #LungCancerCare